Your session is about to expire
← Back to Search
Home-Based Cognitive Training for Multiple Sclerosis (HOBSCOTCH-MS Trial)
N/A
Recruiting
Led By Heather A Wishart, PhD
Research Sponsored by Dartmouth-Hitchcock Medical Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Literate, English-speaking with grade 12 or equivalent in education
Self-reported diagnosis of MS
Must not have
Cognitive dysfunction that precludes participation in giving informed consent
History of progressive neurodegenerative disease (dementia)
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline (pre-hobscotch-ms) and post-hobscotch-ms, approximately 9 weeks later.
Awards & highlights
No Placebo-Only Group
Summary
This trial is testing whether a program called HOBSCOTCH, which helps people with epilepsy manage their condition at home, can be adapted and used by people with multiple sclerosis (MS). The trial
Who is the study for?
This trial is for people aged 20-65 with MS who feel they have memory or cognitive issues. They must be able to read and speak English, have completed at least a grade 12 level of education, and have access to a telephone and the internet.
What is being tested?
The HOBSCOTCH program for epilepsy self-management is being tested to see if it can help improve the quality of life for those with MS. Participants will attend nine virtual sessions with a coach and complete questionnaires about their condition before and after these sessions.
What are the potential side effects?
Since this intervention involves educational training rather than medication, traditional side effects are not expected. However, participants may experience fatigue or stress from attending regular sessions or completing surveys.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I have completed at least 12 years of education and can speak and read English.
Select...
I have been diagnosed with multiple sclerosis.
Select...
I am between 20 and 65 years old.
Exclusion Criteria
You may be eligible for the trial if you check “No” for criteria below:Select...
I am able to understand and give consent for my treatment.
Select...
I have a progressive brain disorder that affects memory and thinking.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ baseline (pre-hobscotch-ms) and post-hobscotch-ms, approximately 9 weeks later.
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline (pre-hobscotch-ms) and post-hobscotch-ms, approximately 9 weeks later.
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Change in quality of life as measured by comparing FAMS-Functional Assessment of Multiple Sclerosis v4.0 scores pre- and post-HOBSCOTCH-MS intervention.
Change in subjective cognition as measured by comparing Neuro-QOL Item Bank v2.0 Cognitive Function scores pre- and post-HOBSCOTCH-MS intervention.
Secondary study objectives
Change in objective cognition as measured by comparing California Verbal Learning Test-III scores pre- and post-HOBSCOTCH-MS intervention.
Change in objective cognition as measured by comparing Symbol-Digit Modalities Test scores pre- and post-HOBSCOTCH-MS intervention.
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
1Treatment groups
Experimental Treatment
Group I: MS Participant with Cognitive DysfunctionExperimental Treatment1 Intervention
Participants will receive the HOBSCOTCH-MS intervention consisting of 1:1 sessions delivered once per week including:
* 1 pre-HOBSCOTCH Session (on webcam or by phone)
* 1 educational session (on webcam)
* 6 HOBSCOTCH intervention sessions (webcam or phone)
* 1 wrap-up session (webcam or phone)
Find a Location
Who is running the clinical trial?
Dartmouth-Hitchcock Medical CenterLead Sponsor
537 Previous Clinical Trials
2,539,706 Total Patients Enrolled
4 Trials studying Multiple Sclerosis
917 Patients Enrolled for Multiple Sclerosis
Heather A Wishart, PhDPrincipal InvestigatorDartmouth-Hitchcock Medical Center
Elaine T Kiriakopoulos, MD, MPH, MScPrincipal InvestigatorDartmouth-Hitchcock Medical Center
3 Previous Clinical Trials
15 Total Patients Enrolled
Share this study with friends
Copy Link
Messenger